Psychedelic Research and Clinical Trials

Explore some of the highest quality research on psychedelics and mental health.

Depression

Addiction

Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression

Depression

Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression

Depression

Depression

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Anxiety, Depression

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Anxiety, Depression

Anxiety, Depression

Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression

Trauma, Depression

Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression

Trauma, Depression

Trauma, Depression

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Depression, Anxiety

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Depression, Anxiety

Depression, Anxiety

Single-Dose Psilocybin Treatment for Major Depressive Disorder

Depression

Single-Dose Psilocybin Treatment for Major Depressive Disorder

Depression

Depression

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomized clinical trial

Depression

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomized clinical trial

Depression

Depression

Trauma, PTSD, cPTSD

Addiction

The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study

Trauma

The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study

Trauma

Trauma

The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)

Trauma

The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)

Trauma

Trauma

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers

Trauma

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers

Trauma

Trauma

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder

Trauma

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder

Trauma

Trauma

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy

Trauma

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy

Trauma

Trauma

Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression

Trauma, Depression

Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression

Trauma, Depression

Trauma, Depression

Addiction, Drinking, & Substance Use

Addiction

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

Addiction

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

Addiction

Addiction

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Addiction

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Addiction

Addiction

Long-term follow-up of psilocybin-facilitated smoking cessation

Addiction

Long-term follow-up of psilocybin-facilitated smoking cessation

Addiction

Addiction

Anxiety

Addiction

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Anxiety, Depression

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Anxiety, Depression

Anxiety, Depression

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Depression, Anxiety

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Depression, Anxiety

Depression, Anxiety

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

Nick Martin, M.A. 4/24/24 Nick Martin, M.A. 4/24/24

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

Psilocybin To Treat Alcohol Use Disorder

Read More

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Rob Mudge, M.A. 4/24/24 Rob Mudge, M.A. 4/24/24

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Ibogaine To Treat Opioid Dependence

Read More

Long-term follow-up of psilocybin-facilitated smoking cessation

Nick Martin, M.A. 4/24/24 Nick Martin, M.A. 4/24/24

Long-term follow-up of psilocybin-facilitated smoking cessation

Psilocybin To Treat Tobacco Smoking

Read More